Genomics of peritoneal surface malignancies
Singh J, Sharma A, Ahuja N. Genomics of peritoneal surface malignancies. Journal Of Peritoneum (and Other Serosal Surfaces) 2017, 2 DOI: 10.4081/joper.2017.62.Peer-Reviewed Original ResearchPeritoneal malignancyHyperthermic intraperitoneal chemotherapyPeritoneal surface malignanciesLong-term survivalPrediction of responseAppendiceal neoplasmsIntraperitoneal chemotherapySurface malignanciesPeritoneal mesotheliomaPeritoneal metastasisPseudomyxoma peritoneiAggressive cytoreductionColorectal cancerTargeted therapyTerminal diseaseTherapeutic markersClinical decisionMalignancyClinical therapyTherapyGenomic alterationsMetastasisGenomic anomaliesGenomic characterizationCytoreductionLong‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiation